Sangamo Therapeutics Received U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

Presentation

Poster: Zinc Finger Mediated Repression and Replacement of MFN2 Leads to the Rescue of Cellular Disease Phenotype in CMT2A Patient-Derived Cells

Download PDF